Brokerages predict that Catalyst Biosciences Inc (NASDAQ:CBIO) will report earnings per share (EPS) of ($0.94) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Catalyst Biosciences’ earnings, with estimates ranging from ($1.20) to ($0.68). Catalyst Biosciences reported earnings of ($0.54) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 74.1%. The business is scheduled to issue its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that Catalyst Biosciences will report full year earnings of ($3.87) per share for the current year, with EPS estimates ranging from ($4.88) to ($2.86). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Catalyst Biosciences.
Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.18).
Shares of Catalyst Biosciences stock opened at $7.99 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 24.94 and a quick ratio of 24.94. Catalyst Biosciences has a 52 week low of $6.20 and a 52 week high of $26.20.
Institutional investors have recently made changes to their positions in the stock. National Asset Management Inc. raised its holdings in shares of Catalyst Biosciences by 40.0% during the fourth quarter. National Asset Management Inc. now owns 35,000 shares of the biopharmaceutical company’s stock valued at $277,000 after acquiring an additional 10,000 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Catalyst Biosciences by 3.9% during the third quarter. BlackRock Inc. now owns 807,441 shares of the biopharmaceutical company’s stock valued at $8,704,000 after acquiring an additional 30,437 shares in the last quarter. 22NW LP bought a new position in shares of Catalyst Biosciences during the fourth quarter valued at approximately $1,124,000. Bank of New York Mellon Corp raised its holdings in shares of Catalyst Biosciences by 27.5% during the third quarter. Bank of New York Mellon Corp now owns 73,711 shares of the biopharmaceutical company’s stock valued at $794,000 after acquiring an additional 15,900 shares in the last quarter. Finally, Requisite Energy Fund I LP bought a new position in Catalyst Biosciences in the fourth quarter worth $256,000. Institutional investors own 68.63% of the company’s stock.
About Catalyst Biosciences
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.